Max Reinhardt is President at Pacira BioSciences, Inc. (PCRX). They have made 10 open-market trades across 2 companies since 2020, most recently 2026-03-05.
CIK 0001780058
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PCRX | 30,324 | $1.1M |
| OFIX | 25,348 | $238K |
| Total | $1.3M |
Shares reported on the most recent Form 4, priced at the 2026-03-06 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OFIX | SELL | 2026-03-04 | 2026-03-06 | $12.74 | $27K | -3.6% | -4.3% | -16.1% |
| OFIX | SELL | 2025-06-11 | 2025-06-13 | $11.64 | $19K | -0.5% | -1.0% | +35.3% |
| PCRX | SELL | 2023-06-06 | 2023-06-07 | $38.42 | $83K | +9.4% | +1.4% | -7.0% |
| PCRX | SELL | 2022-10-07 | 2022-10-11 | $58.00 | $80K | -7.4% | -6.1% | -34.0% |
| PCRX | SELL | 2022-06-06 | 2022-06-08 | $61.56 | $497K | -9.5% | -2.7% | -12.5% |
| PCRX | SELL | 2022-04-21 | 2022-04-25 | $73.25 | $720K | -16.3% | -21.1% | -25.4% |
| PCRX | SELL | 2022-04-18 | 2022-04-20 | $73.27 | $4.1M | -1.2% | -15.5% | -28.0% |
| PCRX | SELL · 10b5-1 | 2021-07-02 | 2021-07-06 | $59.76 | $25K | -3.3% | +7.2% | -13.5% |
| PCRX | SELL | 2021-06-04 | 2021-06-08 | $60.78 | $287K | -1.9% | -7.4% | -7.2% |
| PCRX | SELL · 10b5-1 | 2021-01-06 | 2021-01-08 | $60.81 | $7K | +0.4% | +9.4% | -1.1% |
| PCRX | SELL | 2020-11-13 | 2020-11-17 | $63.38 | $1.6M | -5.8% | -6.4% | +15.5% |
| PCRX | SELL | 2020-09-17 | 2020-09-21 | $59.85 | $1.7M | +0.5% | -9.3% | -2.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.